Physician profile
Stephen Imbeau
NPI 1750448189
$3,156.40
in general payments reported to CMS, 2019-2025
20 companies · $96.89 in 2025
The $96.89 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $353 · 2021: $437 · 2022: $612 · 2023: $757 · 2024: $559 · 2025: $96.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $976.35 | 2019-2025 | Haegarda, Andembry |
| Pfizer INC. | $367.10 | 2019-2024 | |
| Genzyme Corporation | $338.39 | 2019-2024 | |
| Grifols USA, LLC | $206.80 | 2019-2023 | Xembify |
| Novartis Pharmaceuticals Corporation | $206.60 | 2019-2024 | |
| Optinose US, INC. | $152.31 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.84 | 2020-2024 | Cuvitru |
| Pharming Healthcare, INC. | $116.61 | 2020-2023 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $114.94 | 2019-2023 | Dupixent |
| Glaxosmithkline, LLC. | $111.79 | 2020-2023 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $67.52 | 2019-2023 | Airsupra |
| Bio Products Laboratory USA, INC. | $66.78 | 2021-2022 | |
| Genentech USA, INC. | $46.07 | 2021-2024 | Xolair |
| Biocryst US Sales Co., LLC | $39.21 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $34.95 | 2022 | |
| Merck Sharp & Dohme LLC | $29.01 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $27.16 | 2021 | |
| Jubilant Hollisterstier LLC | $17.44 | 2021 | |
| Alk-Abello, INC | $17.15 | 2023 | Grastek, Odactra, Ragwitek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Imbeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.